Search results for "Non melanoma"
showing 2 items of 2 documents
p53 mutations are common in human papillomavirus type 38-positive non-melanoma skin cancers
2004
Copyright © 2003 Elsevier Ireland Ltd. All rights reserved.
Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab
2023
BackgroundMerkel cell carcinoma (MCC) is a rare and aggressive skin cancer, associated with a worse prognosis. The Immune Checkpoint Inhibitors (ICIs) avelumab and pembrolizumab have been recently approved as first-line treatment in metastatic MCC (mMCC). The clinical observation of improved outcomes in obese patients following treatment with ICIs, known as the “obesity paradox”, has been studied across many types of tumors. Probably due to the rarity of this tumor, data on mMMC patients are lacking.Patients and methodsThis is an observational, hospital-based, study to investigate the role of Body Mass Index (BMI) as predictive biomarker of ICI response in mMCC patients treated with aveluma…